A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
This study reports the isolation of two specific monoclonal antibodies from a convalescent covid-19 patient. These antibodies show potent in-vitro neturalization of SARS-CoV-2. One of the antibodies was shown to inhibit SARS-CoV-2 infection in rhesus monkeys. The work also conducts structural studies that show one of the antibodies recognizes part of the receptor binding domain of SARS-CoV-2.